i2o Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- i2o Therapeutics's estimated annual revenue is currently $1.4M per year.
- i2o Therapeutics's estimated revenue per employee is $99,643
- i2o Therapeutics's total funding is $7.7M.
Employee Data
- i2o Therapeutics has 14 Employees.
- i2o Therapeutics grew their employee count by -7% last year.
i2o Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | VP, Research and Program Management | Reveal Email/Phone |
2 | Senior Director Technology Development | Reveal Email/Phone |
3 | Animal/ Laboratory Technician | Reveal Email/Phone |
4 | Chairman, President & CEO | Reveal Email/Phone |
5 | Research Associate | Reveal Email/Phone |
6 | Research Scientist | Reveal Email/Phone |
7 | Research Associate | Reveal Email/Phone |
8 | Chairman, President and CEO | Reveal Email/Phone |
9 | Research Scientist | Reveal Email/Phone |
10 | Research Scientist | Reveal Email/Phone |
i2o Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 1 | -50% | N/A | N/A |
#3 | $5.1M | 33 | 22% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 2 | -60% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | N/A | 11 | 10% | N/A | N/A |
#10 | $5.4M | 29 | 0% | N/A | N/A |
What Is i2o Therapeutics?
i2o Therapeutics is a biotech company developing safe and effective oral formulations of therapies traditionally limited to injections.
keywords:N/A$7.7M
Total Funding
14
Number of Employees
$1.4M
Revenue (est)
-7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $11.9M | 14 | -78% | $116.2M |
#2 | $1.2M | 14 | N/A | N/A |
#3 | $1.4M | 14 | -7% | N/A |
#4 | $1.5M | 14 | -12% | N/A |
#5 | $1.7M | 14 | 17% | N/A |